Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pain drugs
Biotech
Vertex inches closer to acute pain market as FDA accepts VX-548
Vertex is inching closer to bringing a non-opioid pain med to market, with the FDA accepting an NDA submission for VX-548, now dubbed suzetrigine.
Gabrielle Masson
Apr 18, 2024 10:50am
Latigo raises $135M to catch up to Vertex in chronic pain
Feb 14, 2024 5:00am
Seizure drug mechanism could treat osteoarthritis
Jan 5, 2024 10:22am
Confo hands baton to Lilly for non-opioid pain med in $40M deal
Mar 2, 2023 5:00am
Biohaven pain spray aces test amid C-suite shake-up
Dec 6, 2021 10:00am
Non-opioid pain drug indirectly blocks a key ion channel
Nov 10, 2021 2:00pm